Research

Area 2

Applied Research on Infectious Respiratory Diseases, Critical Patients and Lung Cancer

Team manager
Antoni Torres
(Hospital Clínic)
ATORRES(ELIMINAR)@clinic.ub.es

Strategic objectives

1. Study of community-acquired and nosocomial respiratory infections and respiratory infections in immunosuppressed patients.

2. Study of invasive and noninvasive mechanical ventilation in acute respiratory failure, with special interest in weaning from artificial ventilation.

3. Study of exacerbations of COPD and the implication of bacterial, viral and fungal infectious agents.

4. Pathophysiologic studies and treatment in an animal model of ventilator-associated pneumonia.

5. Study of the resistance of microorganisms to antibiotics and antituberculosis drugs.

6. Study of the transmission of tuberculosis.

7. Studies of human research in animal models of sleep apnea syndrome.

8. Multicenter studies in relation to sleep respiratory pathology and the cardiovascular apparatus.

9. Epidemiology and diagnosis of lung cancer.

For further information:
www.idibapsrespiratoryresearch.org

Main lines of research

1. Epidemiology, prevention, diagnosis and new treatments for ventilator-associated pneumonia. Microorganism resistance. Study of biofilm in endotracheal tubes.

2. Epidemiology and diagnosis of community-acquired pneumonia. Multicenter studies in community-acquired pneumonia. New treatments. Microorganism resistance.

3. Studies of the risk factors, microbiology and outcomes of health care associated pneumonia (HCAP).

4. Etiopathogenesis, bronchial infection and inflammation in patients with chronic obstructive pulmonary disease (COPD). Role of infection in exacerbations of the disease. Study of the bronchial and associated systemic response. Analysis of risk factors and outcomes in exacerbations. Smoking. Epidemiology and diagnosis of alpha-1-antitrypsin.

5. Chronic pulmonary infections: bronchiectasis, immunodeficiencies and adult cystic fibrosis. Control of bronchial colonization. Study of the bronchial inflammatory and associated systemic response. New therapeutic forms (nebulizer antibiotic treatment). Replacement therapy with immunoglobulin.

6. Infectious pulmonary complications in immunocompromised patients. Evaluation of etiologic factors. Optimization of diagnostic techniques. Study of the bronchial inflammatory and associated systemic response. Analysis of outcome factors.

7. Invasive and noninvasive mechanical ventilation: Epidemiology, cost-effectiveness and pathophysiology. New techniques. Weaning from mechanical ventilation: role of the inflammatory response and post-extubation respiratory failure.

8. Study of the pharmacokinetics of antibiotics and other drugs in ventilated and nonventilated patients.

9. Tuberculosis and mycobacteriosis: epidemiology and molecular diagnosis, drug-resistance mechanisms.

10. Pig animal model of acute lung injury due to P aeruginosa and MR S aureus: study of new adjuvant drugs in the treatment of pneumonia, study if new antibiotics, prevention of VAP, new forms of mechanical ventilation.

11. Chronic models of sleep apnea.

12. Basic molecular biology, epidemiology and diagnosis of lung cancer.

13. European studies of respiratory infections. Participation in the GRACE, MOSAR and THERAEDGE projects that study respiratory infections in the community, in hospitals, and new diagnostic methodologies, respectively.